Graft-versus-Host Disease
Conditions
Brief summary
A phase II clinical study to assess the efficacy of short-term everolimus as prophylaxis for Graft-versus-Host disease (GvHD) in addition to post-transplantation cyclophosphamide after allogeneic hematopoietic stem cell transplantation in patients with haematological malignancies
Detailed description
Title of the clinical study: A single-centre study of Certican (everolimus) as Prophylaxis for Graft-versus-Host Disease following Post-Transplantation Cyclophosphamide after Allogeneic Stem Cell Transplantation (OCTET-EVER) Indication: Patients with haematological malignancies after allogeneic haematopoietic stem cell transplantation with a matched related or unrelated donor following reduced intensity conditioning and post-transplantation cyclophosphamide Phase: Phase II clinical study Type of study, study design, methodology: Single centre single arm clinical trial, A'Hern's single stage phase II procedure Number of subjects: 20 (17 total evaluable) Primary study objective To assess the efficacy of short-term everolimus as GvHD prophylaxis in addition to post-transplantation cyclophosphamide after allogeneic hematopoietic stem cell transplantation in patients with haematological malignancies and to describe the influence of the modified immunosuppression concept on the incidence and severity of acute GvHD, relapse rates, minimal residual disease, immune reconstitution and chimerism. Medical condition or disease to be investigated: • Patients with haematological malignancies after allogeneic haematopoietic stem cell transplantation with a matched related or unrelated donor following reduced intensity conditioning and post-transplantation cyclophosphamide Name of investigational medicinal product (IMP): Everolimus (Certican®) Investigational medicinal product - dosage and method of administration: 1,5mg per os twice a day (target blood level 5 to 10ng/ml) from day +5 to day +100 after allogeneic stem cell transplantation Duration of treatment: The treatment will be given from day +5 to day +100 after allogeneic stem cell transplantation. The observation time will last from day +5 to day +130. Incidence of chronic GvHD, overall survival and relapse incidence will be recorded on d+365 and d+720 after transplant.
Interventions
DRUGEverolimus
GvHD prophylaxis
Sponsors
University of Cologne
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with haematological malignancies after allogeneic haematopoietic stem cell transplantation with a matched related or unrelated donor following reduced intensity conditioning and post-transplantation cyclophosphamide Principal inclusion criteria: • Written informed consent
Exclusion criteria
* Known intolerance to everolimus * Presence or history of Microangiopathy * Presence of uncontrolled infections * Severe organ dysfunction defined as: * Cardiac left ventricular ejection fraction (LVEF) of less than 35% * Diffusing lung capacity (DLCO) of less than 40% * Total lung capacity (TLC) of less than 40% * Forced expiratory volume (FEV1) of less than 40% * Total bilirubin \>3mg/dl * Creatinine-clearance of less than 40 ml/min * Pregnancy or breast feeding * Participation in other experimental drug trials
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of acute GvHD III-IV° until day +100 after allogenic stem cell transplantation | day 100 after transplantation | GvHD |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | 720 days after transplantation | OS |
| Incidence of acute GvHD II-IV° until day +100 after allogenic stem cell transplantation | day 100 after transplantation | GvHD |
| Incidence of severe chronic GvHD | 720 days after transplantation | cGvHD |
| Incidence of overall chronic GvHD | 720 days after transplantation | cGvHD |
| Non-relapse mortality | 720 days after transplantation | NRM |
| Immune reconstitution | day 100 after transplantation | Number of CD3, CD4, CD8, CD20 and CD56 positive cells in peripheral blood |
| Engraftment | day 100 after transplantation | absolute neutrophil count \> 500/ul and platelet count \> 50.000/ul |
| Chimerism | day 100 after transplantation | % donor cells in peripheral blood or bone marrow |
| Relapse incidence | 720 days after transplantation | Relapse |
Countries
Germany
Outcome results
None listed